Accounts filed on 31-08-2023

Accounts filed on 31-08-2023

IMMUNOPHARMA CONSULTING LTD - Company Information

Print Friendly Version

06617668falseresearch and development on biotechnology2022-09-012023-08-31http://www.companieshouse.gov.uk/2022-08-31http://www.companieshouse.gov.uk/pt:ShareCapital2022-08-31http://www.companieshouse.gov.uk/cd:Director12022-09-012023-08-31http://www.companieshouse.gov.uk/pt:ShareCapital2023-08-31http://www.companieshouse.gov.uk/cd:Director22022-09-012023-08-31http://www.companieshouse.gov.uk/cd:Director32022-09-012023-08-31http://www.companieshouse.gov.uk/cd:OrdinaryShareClass12022-09-012023-08-31http://www.companieshouse.gov.uk/cd:RegisteredOffice2022-09-012023-08-31http://www.companieshouse.gov.uk/cd:AuditExemptWithAccountantsReport2022-09-012023-08-31http://www.companieshouse.gov.uk/pt:CurrentFinancialInstruments2023-08-31http://www.companieshouse.gov.uk/pt:CurrentFinancialInstruments2022-08-31http://www.companieshouse.gov.uk/2022-09-012023-08-31http://www.companieshouse.gov.uk/2022-08-31http://www.companieshouse.gov.uk/cd:FRS1022022-09-012023-08-31http://www.companieshouse.gov.uk/2023-08-31http://www.companieshouse.gov.uk/cd:FullAccounts2022-09-012023-08-31http://www.companieshouse.gov.uk/cd:PrivateLimitedCompanyLtd2022-09-012023-08-31iso4217:GBPxbrli:sharesxbrli:pure
Registered number: 06617668
IMMUNOPHARMA CONSULTING LTD
ACCOUNTS
FOR THE YEAR ENDED 31/08/2023
Prepared By:
LHM ACCOUNTANTS
Incorporated Financial Accountants
20 Westlands Way
Oxted
Surrey
RH8 0ND
IMMUNOPHARMA CONSULTING LTD
ACCOUNTS
FOR THE YEAR ENDED 31/08/2023
DIRECTORS
Mrs A E Crowe
Mr J S Crowe
Mr J Crowe
SECRETARY
P K Manster
REGISTERED OFFICE
20 WESTLANDS WAY
OXTED
SURREY
RH8 0ND
COMPANY DETAILS
Private company limited by shares registered in EW - England and Wales, registered number 06617668
BANKERS
National Westminster Bank Plc
ACCOUNTANTS
LHM ACCOUNTANTS
Incorporated Financial Accountants
20 Westlands Way
Oxted
Surrey
RH8 0ND
IMMUNOPHARMA CONSULTING LTD
ACCOUNTS
FOR THEYEARENDED31/08/2023
CONTENTS
Page
Directors' Report-
Accountants' Report-
Statement Of Comprehensive Income-
Balance Sheet3
Notes To The Accounts4
The following do not form part of the statutory financial statements:
Trading And Profit And Loss Account-
Profit And Loss Account Summaries-
IMMUNOPHARMA CONSULTING LTD
BALANCE SHEET AT 31/08/2023
20232022
Notes££
CURRENT ASSETS
Cash at bank and in hand110,93397,204
110,93397,204
CREDITORS: Amounts falling due within one year332,20728,066
NET CURRENT ASSETS78,72669,138
TOTAL ASSETS LESS CURRENT LIABILITIES78,72669,138
CAPITAL AND RESERVES
Called up share capital4100100
Profit and loss account78,62669,038
SHAREHOLDERS' FUNDS78,72669,138
For the year ending 31/08/2023 the company was entitled to exemption under section 477 of the Companies Act 2006 relating to small companies.
The members have not required the company to obtain an audit in accordance with section 476 of the Companies Act 2006.
The directors acknowledge their responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of accounts.
These accounts have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.
The directors have decided not to deliver to the registrar a copy of the company's profit and loss account.
Approved by the board on 12/03/2024 and signed on their behalf by
.............................
Mr J S Crowe
Director
IMMUNOPHARMA CONSULTING LTD
NOTES TO THE ACCOUNTS
FOR THE YEAR ENDED 31/08/2023
1. ACCOUNTING POLICIES
1a. Basis Of Accounting
The accounts have been prepared under the historical cost convention.
The accounts have been prepared in accordance with FRS102 section 1A - The Financial Reporting Standard applicable in the UK and Republic of Ireland and the Companies Act 2006 .
2. EMPLOYEES
20232022
No.No.
Average number of employees--
3. CREDITORS: AMOUNTS FALLING DUE WITHIN ONE YEAR
20232022
££
UK corporation tax10,66914,369
Directors current account20,92413,101
Accruals614596
32,20728,066
4. SHARE CAPITAL 20232022
££
Allotted, issued and fully paid:
100 Ordinary shares of £1 each100100
100100